|
��չ����
|
|
| ������Ϣ | |
 |
Supporting info |
|
PDFȫ�� |
|
[HTMLȫ��] |
|
����� |
| �����뷴�� | |
|
�������ù����� |
|
���� |
|
Email Alert |
|
���·��� |
|
���������Ϣ |
| ���Ĺؼ���������� | |
|
�������� |
| ��������������� | |
|
��˫� |
|
���� |
| PubMed | |
|
Article by Chen,S.Y |
|
Article by Jiang,g |
��CTLA-4����¡�������ƺ������Ľ�չ
��˫�,����
����ҽѧԺ����ҽԺƤ����
���Ժ�������������Ϯ��ǿ��Ԥ��ϲĿǰ�����緶Χ��������δ���˵�����֮һ���о����֣���CTLA-4����¡������������ߺ���������ƽ�������ںͿ���Ч�ʣ���һ�����͵������������õİ�������ҩ���һ�о�ָ���������������ߵ��ڵ����������������о�����Ҫ���ã�Ϊ���ں����������о��ṩ���µ�̽�����������˼·��
Anti?۲cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibodies in the treatment of malignant melanoma
The treatment of malignant melanoma remains a difficult problem in the world because of its strong invasion and poor prognosis. It has been evidenced that anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) monoclonal antibodies notably increase the average survival and objective response rate of patients with melanoma, and are considered to be a novel immune-based targeted therapeutic agent. The interference in inhibitory immune regulatory checkpoints has been demonstrated to play an important role in tumor immunotherapy, which may provide new directions and ideas for the treatment of advanced melanoma.